Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03475628 | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma(REBUILD) | unknown | Phase 2 | 57 | Hellenic Society of HematologyOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 |
| clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03373526 | Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation | unknown | N/A | 50 | Daniel Godoy MartinezOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT02885623 | Role of CX3CR1-expressing Cells in Hematologic Malignancy | unknown | — | 50 | Saint Vincent's Hospital, KoreaOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02248428 | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma(CTd) | unknown | Phase 3 | 130 | Jinling Hospital, ChinaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02086942 | Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. | unknown | Phase 2 | 94 | Yongping ZhaiOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03244930 | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | unknown | Phase 2 | 20 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03210753 | Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma | unknown | — | 400 | National Taiwan University HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT03122327 | cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study. | unknown | — | 200 | Peking Union Medical College HospitalOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT03089411 | Collection of Additional Data Followed the Study IFM 2013-04 | unknown | — | 340 | Nantes University HospitalOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02087657 | Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation(Auto-HBO) | unknown | N/A | 20 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02572596 | Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients | unknown | N/A | 200 | Wang GuorongOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02981199 | Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients | unknown | N/A | 80 | Chen WenmingOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02916420 | Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 73 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02184897 | Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization | unknown | N/A | 24 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01671826 | Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years(LATMM) | unknown | — | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02797041 | Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.(REBOUND) | unknown | — | 100 | IRCCS Centro di Riferimento Oncologico della BasilicataOTHER | 0 | Jun 14, 2016 | clinicaltrials |
| NCT02791217 | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | unknown | — | 100 | Assuta Medical CenterOTHER | 0 | Jun 6, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | unknown | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02109861 | Microdose Study of Melphalan, Bortezomib and Dexamethasone(Phase-0-MM) | unknown | Early Phase 1 | 6 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02624440 | Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma(SUTRICA) | unknown | Phase 2 | 300 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02145715 | Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma(MUKsix) | unknown | Phase 1 / Phase 2 | 54 | Prof Jamie CavenaghOTHER | 1 | Jun 26, 2015 | clinicaltrials |
| NCT02467647 | The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy(HLJDT-2016) | unknown | Phase 1 | 500 | Wuhan UniversityOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02336386 | CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma | unknown | Phase 3 | 100 | Beijing Chao Yang HospitalOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT02093910 | Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02248402 | Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma(Vax-DC/MM) | unknown | Phase 1 / Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT02078518 | Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors | unknown | — | 75 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT02027220 | Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT02024815 | Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. | unknown | Phase 3 | 100 | Lithuanian University of Health SciencesOTHER | 1 | Dec 31, 2013 | clinicaltrials |
| NCT02023671 | IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE | unknown | — | 70 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Dec 30, 2013 | clinicaltrials |
| NCT01619358 | Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma | unknown | — | 150 | National University Hospital, SingaporeOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT01923935 | Busulfan and Melphalan Conditioning in Multiple Myeloma | unknown | Phase 2 | 105 | Chonnam National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT01892852 | Acupuncture for Chemotherapy-induced Peripheral Neuropathy | unknown | N/A | 36 | Pusan National University HospitalOTHER | 1 | Jul 17, 2013 | clinicaltrials |
| NCT01868828 | A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | unknown | Phase 4 | 50 | Peking University People's HospitalOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01695590 | Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Prolexys PharmaceuticalsINDUSTRY | 1 | Jun 4, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 23, 2018source: clinicaltrials